시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 대사증후군 시장(2023년판) : 적응증별, 분자 유형별, 투여 경로별, 지역별, 국가별 분석, 시장 인사이트 및 예측(2018-2028년)
Global Metabolic Syndrome Market (2023 Edition): Analysis By Indication (NASH, IRS, Hypercholesterolemia, Obesity Syndrome, Others), By Molecule Type, Route of Administration, By Region, By Country: Market Insights and Forecast (2018-2028)
상품코드 : 1283964
리서치사 : Azoth Analytics
발행일 : 2023년 06월
페이지 정보 : 영문 270 Pages
 라이선스 & 가격 (부가세 별도)
US $ 2,400 ￦ 3,324,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 3,000 ￦ 4,155,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 대사증후군 시장 규모는 2021년 225억 달러에서 2028년 말까지 289억 달러에 달할 것으로 예상되며, 2024-2028년간 연평균 46.30%의 성장률을 보일 것으로 예상됩니다.

이 보고서는 세계 대사증후군(Metabolic Syndrome) 시장에 대해 조사 분석했으며, 시장 규모와 예측, 지역 및 부문별 분석, 업계 동향 등의 정보를 전해드립니다.

목차

제1장 시장 배경

제2장 전략적 추천 사항

제3장 세계의 대사증후군 시장 : 실적과 예측(2018년-2028년)

제4장 세계의 대사증후군 시장, 지역 분석

제5장 아메리카의 대사증후군 시장 : 실적과 예측(2018년-2028년)

제6장 유럽의 대사증후군 시장 : 실적과 예측(2018년-2028년)

제7장 아시아태평양의 대사증후군 시장 : 실적과 예측(2018년-2028년)

제8장 중동 및 아프리카의 대사증후군 시장 : 실적과 예측(2018년-2028년)

제9장 시장 역학

제10장 업계 생태계 분석

제11장 경쟁 포지셔닝

LSH
영문 목차

영문목차

Executive Summary

Azoth Analytics has released a research report titled "Metabolic Syndrome Market (2023 Edition)" which provides a complete analysis of the global Metabolic Syndrome industry in terms of market segmentation By Indication (Insulin Resistance Syndrome, Hypercholesterolemia, Obesity Syndrome, Nonalcoholic steatohepatitis, Other Indications), By Molecule Type (Small Molecule, Protein, RNA/DNA, Other Molecules) and By Route of Administration (Oral, Subcutaneous, Other ROA) for the historical period of 2018-2022, the estimated year 2023 and the forecast period of 2024-2028.

The research study is global in nature and covers a detailed analysis of the market in the Americas (U.S., Canada, Rest of Americas), Europe (France, U.K, Italy, Spain, Germany, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), and the Middle East and Africa. Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, demand for future forecast, and so on.

The research study also assesses market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Metabolic Syndrome Market is expected to generate USD 28.9 billion by the end of 2028, up from USD 22.5 billion in 2021. Metabolic syndrome is a complicated disorder characterized by a group of linked metabolic abnormalities that raise the risk of cardiovascular disease, type 2 diabetes, and other major health problems. It is a global health issue with significant public health implications. Central obesity, high blood pressure, dyslipidemia (abnormal lipid profile), and reduced metabolism of glucose are important components of metabolic syndrome. During the forecast period, 2024-2028, the Global Metabolic Syndrome market is expected to expand at a CAGR of 46.30%.

In addition, as the healthcare sector moves toward a more preventive and customized approach, there is a greater emphasis on early detection and management to reduce the risk of metabolic syndrome-related challenges. This pattern is likely to fuel demand for diagnostic tests, treatment options, and digital health solutions.

Companies are working on creating novel drugs that address many aspects of metabolic syndrome at the same time. This strategy seeks to enhance patient outcomes while reducing the need for multiple drugs. Furthermore, technological advances such as wearable gadgets and mobile applications have evolved to assist individuals in monitoring their health metrics and successfully managing their condition.

Among the Indication type, Insulin Resistance Syndrome holds the maximum share in the market. The global market for therapeutics of Insulin resistance Metabolic Syndrome is expected to grow in the coming years, driven by the increasing prevalence of Diabetes.

This study also provides a competitive landscape of the industry and profiles leading players in the Global Metabolic Syndrome Market including Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceutical, Sanofi, AstraZeneca, Amgen, Merck Co., Inc., Johnson & Johnson, Pfizer, and Abbott. The company profiling includes critical information such as a business overview, Drug Molecule type and other products, key financials, and recent events and developments. Overall, the report provides a detailed overview of the Global Metabolic Syndrome Market, which will assist industry consultants, equipment manufacturers, existing players looking for expansion opportunities, new players looking for opportunities, and other stakeholders in aligning their market-centric strategies with current and expected future trends.

Scope of the Report:

Table of Contents

1. Market Background

2. Strategic Recommendations

3. Global Metabolic Syndrome Market: Historic and Forecast (2018-2028)

4. Global Metabolic Syndrome Market, Region Analysis

5. Americas Metabolic Syndrome Market: Historic and Forecast (2018-2028)

6. Europe Metabolic Syndrome Market: Historic and Forecast (2018-2028)

7. Asia-Pacific Metabolic Syndrome Market: Historic and Forecast (2018-2028)

8. Middle-East & Africa Metabolic Syndrome Market: Historic and Forecast (2018-2028)

9. Market Dynamics

10. Industry Ecosystem Analysis

11. Competitive Positioning

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기